



Animal Health Research Journal

P-ISSN : 2356-7767 On Line-ISSN : 2535-1524

Journal Homepage: <https://animalhealth.ahri.gov.eg/>

Research Paper

Efficacy of *Bacillus licheniformis* on *Clostridium perfringens*-inducing necrotic enteritis in broilers

Salma, S. Labeab*; Amira, S. El-rafi**; Walaa, A. El-Sayed***
and Rasha, B. El-Sharkawy****

Researcher of Microbiology*; Senior Researcher of Microbiology**; Researcher of Pharmacology***; Researcher of Clinical Pathology****; AHRI, Zagazig, Animal Health Research Institute (Zagazig Provincial Laboratory), (ARC)

Received in 4/5/2025
Received in revised from
25/5/2025
Accepted in 29/6/2025

Keywords:

Probiotic,
GalliproTect®,
Clostridium perfringens,
Bacillus licheniformis,
Broilers,
BW, BWG, and FCR,
Antioxidant status,
Immunology,
PCR and
Immunohistochemistry
(IHC)

Abstract

C*lostridium perfringens* is a major bacterial threat in poultry, responsible for necrotic enteritis (NE), which negatively affects bird health and production. Due to restrictions on antibiotics, probiotics are being investigated as alternatives probiotics (*Bacillus species*), in particular *B. licheniformis*, are non-pathogenic microorganisms that reduced intestinal inflammation and preserved the intestinal morphology in broilers challenged with *C. perfringens*. A total of 150 samples from the liver and intestine of broiler chickens from different farms in Sharkia Governorate; 70 of these isolates came from intestinal samples, 80 from liver tissue samples yielded 60 *C. perfringens* isolates. Using Real Time PCR, 60 strains of *C. perfringens* from healthy and sick broilers with gastrointestinal problems were shown to have the alpha toxin gene (*cpa*). Type A is the most common type found in *C. perfringens* samples from infected hens, while both *cpa* and *cpb* genes were detected in only one out of five affected birds. A sensitivity test was performed on 14 antibiotics against *C. perfringens*. For the antibiotics that showed the highest sensitivity, the minimum bactericidal concentration (MBC) and minimum inhibitory concentration (MIC) were measured. Bacitracin Zn was identified as the recommended treatment because the MBC values, which show the concentration needed to kill the bacterium, typically surpass the MIC values. In this study, a total of 120 Commercial Cobb broiler chicks were randomly divided into six equal groups: **Gp. (1)**: normal control group (basal diet only), **Gp. (2)**: infected control group (at day 14, infected with *C. perfringens* type A (1.5×10^8 CFU/mL), **Gp. (3)**: (fed GalliproTect® (8×10^6 CFU/g) from day 1 throughout the experiment, **Gp. (4)**: fed GalliproTect® from day 1 and

Corresponding author: Salma, S. Labeab, Researcher of Microbiology, Zagazig Provincial Laboratory Animal Health Research Institute (AHRI) Dokki, Giza Agriculture Research Center (ARC), Nadi El-Seid Street, Dokki P.O., Giza 12618, Egypt.

Email address: salmasaladin2020@gmail.com

challenged with *C. perfringens* at day 14, **Gp. (5)**: infected and treated with Bacitracin Zinc at 48 hours post-infection, and **Gp. (6)**: challenged at day 14 and treated with GalliproTect® from day 1 in combination with Bacitracin Zinc after infection. The findings showed that early supplementation with GalliproTect® improved growth performance, enhanced blood parameters, and offered protection against *C. perfringens* infection. This study evaluated the effects of GalliproTect®, a probiotic formulated from *B. licheniformis*, as a dietary supplement that promotes bird growth and may serve as a potential alternative to the in-feed antibiotic Bacitracin Zn. The evaluated criteria included immunological response, growth performance, blood chemistry, serum antioxidant levels, and the probiotic's efficacy in reducing NE.

Introduction

Necrotic enteritis is a common and economically damaging disease of broilers caused by *C. perfringens*, a bacterium found in litter and intestinal contents. (Van *et al.*, 2004; Cooper and Songer, 2009 and: Osman Elhariri, 2013 and Alizadeh *et al.*, 2024). Alpha-toxin is the main factor in disease severity, leading to intestinal damage and toxemia. (Timbermont *et al.*, 2009, M'Sadeq *et al.*, 2015 and Villagrán-de la Mora *et al.*, 2020). The poultry feed sector is actively seeking sustainable non-antibiotic alternatives to manage necrotic enteritis (NE) during its initial phases by reducing the populations of *C. perfringens*. (Lyras *et al.*, 2009 and Elleithy *et al.*, 2023). The extensive application of antimicrobial agents for promoting growth and preventing diseases in Canada is raising concerns about the dissemination of antimicrobial resistance in the enteric flora, especially regarding the resistance observed in *C. perfringens* colonies. (ESVAC, 2017). Antimicrobial susceptibility assays provide an in vitro assessment of how sensitive or resistant specific microorganisms are to a variety of medications. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of many potential agents against *C. perfringens* were determined using the agar dilution technique, as advised by the (NCCLS, 2004). In 1945, *Bacillus licheniformis* bacteria produced the antibiotic known as Bacitracin Zn (Hofacre *et al.*, 1998), which is a well-known metallopeptide antibiotic with potent bactericidal properties primarily targeting Gram-positive bacteria (Russell and Strobel, 1988). It works by inhibiting cell wall synthesis, impacting bacterial membranes, leading to a 10.8% increase in chicken body weight, reducing food conversion rate by 31%, and promoting an increase in abdominal fat in

chickens (Butaye *et al.*, 2003). Probiotics are considered potential substitutes for antibiotics and growth enhancers when utilized as a preventive measure against necrotic enteritis triggered by *C. perfringens*. (Cheng *et al.*, 2020; Hussein *et al.*, 2020). Natural feed additives are used to maintain a healthy gut microbiota, as they contain beneficial live microorganisms that can be included in broiler diets to enhance intestinal health, promote growth, boost immunity, and improve the antioxidant status of the birds while preventing harmful microorganisms from attaching, particularly during their early growth stages. (FAO/WHO, 2006 ; Abd Al-Fatah, 2020 and Abd El-Hack *et al.*, 2022). *Bacillus* bacteria, such as *Bacillus subtilis*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus cereus*, and *Bacillus polymyxa*, are among the top microorganisms used for probiotics and direct-fed growth enhancers. (Chang and Yu, 2022). Based on earlier research, *Bacillus licheniformis* (BL) ranks among the most widely used probiotics in the livestock industry due to its resistance to stress and elevated temperatures. Research has indicated that BL can generate various beneficial compounds, including bacteriocin, antimicrobial peptides, and digestive enzymes, which enhance animal performance and support immune system development. (Yang *et al.*, 2021; Additives *et al.*, 2023) and stop *Clostridium* from colonizing the intestines as a growth booster to increase bird growth by producing the enzymes that help break down and absorb nutrients from food (Han *et al.*, 2023).

Immunohistochemistry (IHC) is a valuable diagnostic technique that helps visualize specific bacterial antigens within tissue sections using monoclonal antibodies. The ability of IHC to localize bacterial antigens allows for better understanding of infection progression and the

efficacy of treatment strategies (Kaldhusdal and Hofshagen, 1992). This research focused on the isolation, identification, and assessment of the antimicrobial susceptibility of *C. perfringens* derived from chickens, as well as testing the MIC and MBC for Bacitracin Zinc. The study also examined the effectiveness of *B. licheniformis* and Bacitracin Zinc against *C. perfringens* in broiler hens, along with their role in preventing infections and reducing the severity of necrotic enteritis (NE). Multiplex PCR reaction was utilized to screen for circulating strains and their toxicity. Furthermore, it assessed the effects of probiotic and/or antibiotic supplementation on growth performance, hematological and biochemical parameters, immunological status, and immunohistochemistry (IHC), which is a valuable diagnostic approach for visualizing specific bacterial antigens in tissues.

Material and methods

Samples Collection:

- A total of 150 intestinal and liver samples were gathered from broiler chickens sourced from various farms in Sharkia Governorate. The samples were collected from chickens suspected of infection, aged between 2 to 5 weeks, that exhibited signs of diarrhea, lethargy, and suboptimal growth performance. These samples were carefully transported in ice boxes to the laboratory for the purpose of isolating and identifying *C. perfringens*.

Isolation and identification of *C. perfringens*:

Suspected samples were inoculated into tubes of cooked meat medium and then incubated at 37°C for 24 hours anaerobically (Willis, 1977). Neomycin sulphate (200 µg/ml) was used to streak a loopful of infected fluid media onto 10% sheep blood agar (Smith and Holdeman, 1968; Cruickshank *et al.*, 1975). Colonies of *C. perfringens* have a double zone of hemolysis and are flat and olive in color (Vaikosen and Muller, 2001). Gram-positive non motile bacilli were observed under a microscope. Suspected pure isolates were acquired and identified using the Koneman *et al.*, 1992 techniques. These isolates demonstrated lecithinase activity on egg yolk agar positive (Cruickshank *et al.*, 1975), nitrate reduction, and catalase and indole negative results.

PCR assay:

Real Time PCR targeted *cpa* and *cpb* genes to confirm toxin presence:

RNA extraction:

RNA extraction from tissue samples was applied using QIAamp RNeasy Mini kit (Qiagen, Germany, GmbH) when 200 µl of the sample were added to 600 µl RLT buffer containing 10 µl β-mercaptoethanol per 1 ml, incubated at room temperature for 10 min. One volume of 70% ethanol was added to the cleared lysate, and the steps was completed according to the Purification of Total RNA protocol of the QIAamp RNeasy Mini kit (Qiagen, Germany, GmbH).

Oligonucleotide Primers:

Primers used were supplied from Metabion (Germany) are listed in Table (1)

Toxin	Sequence	Amplified product	Reference
<i>cp alpha</i>	AAGAACTAGTAGCTTACATATCAACTAGTGGTG	65°C 60 min.	YOO <i>et al.</i> , (1997)
	TTTCCTGGGTTGTCCATTTC		
<i>cp beta</i>	TGGAGCGTGAAAGAACTGTTATTA		
	GGTATCAAAAGCTAGCCTGGAATAGA		

SYBR green rt-PCR:

Primers were utilized in a 25- µl reaction containing 12.5µl of the 2x *HERA* SYBR® Green RT-qPCR Master Mix (Willowfort, UK), 1 µl of RT Enzyme Mix (20X), 0.5 µl of each primer of 20 pmol concentration, 3 µl of water, and 5 µl of RNA template. The reaction was performed in a step one real time PCR machine in the Biotechnology Unit, Animal Health Research Institute, Zagazig Branch, Egypt.

Analysis of the SYBR green rt-PCR:

The step one program was used to determine amplification curves and ct values. Using the "ΔΔCt" method described by **Yuan et al. (2006)**, the CT of each sample was compared with that of the positive control group using the following ratio: (2-ct) in order to determine the variation of gene expression on the RNA of the various samples.

Assays for Antimicrobial Susceptibility:

The susceptibility tests were performed using antimicrobial drugs commonly used in clinical practice, as outlined by the British Society for Antimicrobial Chemotherapy (BSAC, 2011), which describes the agar disk diffusion technique (Oxoid, UK) utilized for evaluating the antimicrobial susceptibility of isolates. The antibiotics used in the tests included Ceftriaxone, Rifampicin, Doxycycline, Lincomycin, Clindamycin, Ampicillin, Amoxicillin, Bacitracin Zinc, Vancomycin, Ciprofloxacin, Levofloxacin, Enrofloxacin, Metronidazole, Tylosin, and Tiamulin. Each isolate was cultured in Mueller Hinton agar medium (Oxoid, UK) and incubated overnight in 10% neomycin sheep blood agar. The cultures were then adjusted in saline to achieve an optical density corresponding to McFarland 0.5 standards. Following a 15-minute period, antimicrobial discs were placed on the agar. Interpretation of the results was conducted according to **Martel et al. (2004)** after the plates were incubated anaerobically for 24 hours at a temperature of 37°C.

Determination of MIC and MBC of antimicrobial sensitivity:**1. Bacterial Culture:**

Start with a pure culture of *C. perfringens*, ideally from a fresh isolate or a reference

strain. Subculture the bacteria onto Tryptose Sulfite Cycloserine (TSC) agar or reinforced clostridial medium (RCM) and incubate anaerobically. For MIC/MBC testing, select 10-20 colonies from the agar and inoculate them into fluid thioglycollate broth (FTB) for overnight growth. For more accurate results, ensure the culture is in the logarithmic growth phase by checking the optical density (OD) at 600 nm.

2. Media Preparation:

Prepare Mueller Hinton broth (MHB) and supplement it with 5% lysed horse blood. Sterilize the media by autoclaving. For *C. perfringens* testing, MHB supplemented with blood is crucial for proper growth.

3. Bacitracin Preparation

Obtain a stock solution of bacitracin with a known concentration. Prepare serial dilutions of bacitracin in MHB (e.g., 2-fold serial dilutions) to achieve a desired range of concentrations (e.g., 0.016 to 256 µg/mL).

4. Inoculum Preparation:

Prepare a bacterial suspension from the overnight FTB culture by diluting it in fresh MHB to achieve a desired cell density, typically a 0.5 McFarland standard or a concentration of 5×10^5 CFU/mL.

5. MIC Determination:

Distribute the diluted bacitracin into sterile 96-well plates. Introduce the bacterial suspension to each well containing the bacitracin concentrations. Incubate the plates in anaerobic conditions at 37°C for a duration of 24 hours. Following incubation, evaluate bacterial growth through visual observation (looking for turbidity or a clump of cells at the well's bottom) or by measuring optical density at 600 nm. The MIC is defined as the lowest concentration of bacitracin that prevents visible growth.

6. MBC Determination:

For each well that displays an MIC and concentrations exceeding it, transfer 100 µL to TSC or RCM agar plates. Incubate the agar plates anaerobically at 37°C for a duration of 24 hours. Count the number of colonies present on each plate. The MBC is defined as the

lowest bacitracin concentration that leads to a 99.9% decrease in bacterial colony count in comparison to the original inoculum.

Drugs

-Probiotic: *Bacillus Licheniformis* (GalliproTect®) obtained commercially from Chr. Hanssen company, Denmark. *B. Licheniformis* spores administered at a dose of 500 g / ton of feed (8×10^6 CFU/g) as recommended by the producer. (Veken *et al.*, 2021).

-Antibiotic: Zincbac 150®, Zinc bacitracin feed premix package of 1kg obtained commercially from Arab Company, Egypt, by dose 55 mg/kg feed for 5 days (recommended dose).

-Bacterial inoculum: Toxigenic *C. perfringens* type A, isolated field strain, was established by PCR, the birds were individually challenged by oral gavages with 1 milliliter of 1.5×10^8 CFU at 14 days of age.

Experimental animals:

The present study was conducted at Al-Amoushi chicken farm located in Aga city,

close to Mansoura Governorate, 120 Commercial Cobb chicks were kept in optimal environmental conditions concerning light, temperature, and humidity, and they had unrestricted access to water and standard commercial feed pellets throughout the duration of the experiment.

Experimental design:

In this study, a total of 120 Commercial Cobb broiler chicks were randomly divided into six equal groups: **Gp. (1):** normal control group, **Gp. (2):** infected control group, at 14 days old, birds infected with *C. perfringens* type A (1.5×10^8 CFU/ml), **Gp. (3):** (fed GalliproTect® 500 g /ton of feed (8×10^6 CFU/g) from day 1 and throughout the experiment, **Gp. (4):** fed GalliproTect® from day 1 and challenged with clostridia at 14 day old, **Gp. (5):** antibiotic treated group (infected and treated with Bacitracin Zinc (55 ppm) at 48 hours post-infection), and **Gp. (6):** challenged at day 14 and treated with GalliproTect® from day 1 in combination with Bacitracin Zn after infection.

Table (2). Experimental design:

	Groups		No. of chicks	Type of treatment	Time of blood sampling
The experi- mental Commer- cial Cobb broilers chickens (N = 120)	Experimental Groups broiler chickens after infection	Group 1	20	Fed control diet without medication or bacterial challenge, (- ve control group).	Blood samples were collected from wing veins of 5 chicks per group at the age of 21 and 28 day old using sterile clean tubes
		Group 2	20	Challenged by <i>C. Perfringens</i> in day 14 of age at a dose of (1.5 x10 ⁸ CFU/ ml), and fed control diet. (+ ve control group).	
		Group 3	20	Non infected and fed on (GalliproTect®) at a dose of 8×10 ⁶ CFU /g for feed (500 gm/ton) the whole feeding period).	
		Group 4	20	Fed on (GalliproTect®) at a dose of 8×10 ⁶ CFU /g for feed (500 gm/ton the whole feeding period) and challenged by <i>C. Perfringens</i> at a dose of (1.5 x10 ⁸ CFU/ml) at 14 days of age.	
		Group 5	20	Challenged by <i>C. Perfringens</i> at a dose of (1.5 x10 ⁸ CFU/ml) at 14 days of age and treated with Bacitracin Zn (48 hrs after infection).	
		Group 6	20	Challenged by <i>C. Perfringens</i> at a dose of (1.5 x10 ⁸ CFU/ml) at 14 days of age and treated with (GalliproTect®) at a dose of 8×10 ⁶ CFU /g + Bacitracin Zn after infection.	
Total number			120		

Growth performance:

At the conclusion of each period, growth performance parameters, the body weight gain (BWG) and feed conversion ratio (FCR), were calculated using the body weight (BW) and the average daily feed intake (FI) to assess the impact of the treatments on growth (**Cengiz et al. 2015**). Additionally, clinical signs were recorded daily throughout the experimental period.

Sampling:

- A selection of five birds from each group was made to gather blood samples on the 21th and 28th days of ages. Each blood sample was separated into three parts. The first part was combined with dipotassium salt of EDTA (1 mg/1 mL of blood) for conducting hematological tests. The second part was transferred into a clean centrifuge tube without any anticoagulant to collect serum by centrifugation for biochemical testing. The third part (2 mL of blood) was moved to a sterile plastic centrifuge tube containing heparin (50 I.U./mL) to evaluate phagocytic activity. (**Xue et al., 2011**).

- Liver and intestinal tissue samples were gathered and prepared for immunohistochemistry using antibodies targeted at *C. perfringens* in the Faculty of Science at Zagazig University. (**Meer and Songer, 1997**).

Hematological studies

A complete blood count was performed, measuring factors such as hemoglobin levels, percentage of packed cell volume, red blood cell count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), total white blood cell count, and the differential count of white blood cells. This was accomplished using the Sysmex XT automatic cell counter (2000 IV; located at AHRI Zagazig), following the methodologies outlined by **Thrall et al., (2012)**.

Serum Biochemistry studies:

Biochemical tests were carried out utilizing test kits from Diamond-Egypt in accordance with the manufacturer's guidelines. The assessment of serum total proteins was based on the method described by **Grant et al. (1987)**, while serum albumin levels were determined following the protocol established by **Doumas**

et al. (1981). The activities of liver enzymes, such as alkaline phosphatase (ALP) as outlined by **Kind and King (1954)**, and alanine aminotransferase (ALT) along with aspartate aminotransferase (AST) as per **Reitman and Frankel (1957)**, were measured. Serum levels of uric acid and creatinine were evaluated using commercially available kits, following the manufacturer's instructions. The serum cortisol concentration (Monobind Inc., Lake Forest, CA, sensitivity: 0.25 mg/dl) was analyzed with NS BIOTECH Apparatus using Elisa kits sourced from Diametra company, as referenced by **Loriaux (2017)**.

Determination of serum antioxidative status:

The activities of Superoxide dismutase (SOD) and Catalase (CAT), along with the Malondialdehyde (MDA) concentration in serum, were evaluated using commercially available assay kits from the Nanjing Jiancheng Bioengineering Institute, following the manufacturer's guidelines to assess serum antioxidant capacity. The measurement of CAT activity was carried out according to the technique described by **Senthilkumar et al. (2021)**, while the assessment of Superoxide dismutase activity was performed using the method outlined by **Oberley and Spitz (1985)**. Malondialdehyde levels were quantified based on the protocol established by **Thrall et al. (2012)**.

Immunological studies:

- Serum IgG levels were assessed using a sandwich ELISA technique according to **Lovland et al. (2003)**.

- The evaluation of phagocytic activity, including both phagocytic percentage and phagocytic index, was conducted following the method outlined by **Platt and Fineran (2015)**.

Immunohistochemistry detection of *C. perfringens* Alpha-toxin in Liver and intestinal tissues of broiler chickens:

Immunohistochemistry (IHC): Liver and intestinal tissues that had been fixed in formalin and embedded in paraffin (4–5 µm thick) were subjected to deparaffinization and rehydration. Antigen retrieval was conducted using a citrate buffer (pH 6.0) in a microwave. The activity of endogenous peroxidase was inhibited with 3%

hydrogen peroxide. The sections were incubated at 4°C overnight with a rabbit polyclonal antibody targeting *C. perfringens* alpha-toxin (at a 1:200 dilution). Following this, a biotinylated secondary antibody and streptavidin–HRP complex were applied, and DAB chromogen was used for visualization. Lastly, the sections were counterstained with hematoxylin and observed under a light microscope (Meer and Songer, 1997).

Statistical analysis:

The statistical evaluations were conducted using SPSS for Windows (Version 18.0; SPSS Inc., Chicago, IL). The differences among the experimental groups were assessed using one-way analysis of variance (ANOVA). If a significant difference was identified through the one-way ANOVA, individual group comparisons were performed with the post hoc Fisher's least significant difference (LSD) test. The results are presented as mean $\pm$ standard error of mean. A P-value of less than 0.05 was considered significant (Kinnear and Gray, 2006).

Results

Isolation and identification of *C. perfringens*:

Bacteriological examination revealed colonies with a characteristic double zone of hemolysis and olive coloration on blood agar. Microscopic evaluation showed Gram-positive non motile bacilli. Suspected pure isolates were acquired and identified. These isolates demonstrated lecithinase activity on egg yolk agar positive, nitrate reduction, and catalase and indole negative results.

Molecular confirmation by Real Time PCR as shown in Fig (1):

The amounts of alpha and beta toxins in various groups were displayed by the results of real-time PCR as in Fig (1). GalliproTect® inhibits the growth of *C. perfringens* type A and formation of its toxins.




Fig. (1). Gene expression levels of *C. perfringens alpa* (cpa) & *beta* toxins (cpb) in all experimental groups Cpa& cpb expression were quantified& compared between all groups
Statistical significance as follow: ns (not significant), p< 0.05(*) and p <0.01 (**).

Table (3) Antimicrobial susceptibility of *C. perfringens* isolates: inhibition zones of different antibiotics MIC and MBC :

The results of the antibiotic susceptibility tests performed on *C. perfringens* were presented. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were established for four promising

antibiotic drugs: Enrofloxacin, Bacitracin Zn, Lincomycin, and Clindamycin. Bacitracin Zn was identified as the preferred medication, with the concentration necessary to eliminate the bacterium represented by the MBC values, which typically exceed the MIC values. The MIC₅₀ and MIC₉₀ ranged from 0.25 to 0.5 µg/ml. (NCCLS, 2004).

Antibiotic	Disc Content (µg)	Inhibition Zone (mm)	MIC 50 (µg/mL)	MBC 90 (µg/mL)
Ceftriaxone	30	24	-	-
Ampicillin	10	22	-	-
Amoxicillin	25	20	-	-
Vancomycin	30	25	-	-
Enrofloxacin	5	24	0.5	1.0
Bacitracin Zinc	10	30-36	0.25	0.5
Ciprofloxacin	5	23	-	-
Levofloxacin	5	22	-	-
Metronidazole	5	21	-	-
Lincomycin	15	25	0.25	0.5
Clindamycin	2	20	1.0	2.0
Rifampicin	5	19	-	-
Tylosin	30	18	-	-
Tiamulin	30	22	-	-

MIC 50: MIC that inhibit 50% of the bacteria

MIC 90: MIC that inhibit 90% of the bacteria

Immunohistochemistry (IHC):

Immunohistochemistry staining outcomes for intestinal epithelial cells and hepatocytes revealed no positive staining in control negative group (G1), suggesting the absence of *C. perfringens*. Conversely, the positive control group (G2) displayed intense brown staining,

indicating significant colonization. In the meantime, (G3) showed weak staining and (G4) exhibited moderate immunoreactivity, while (G5) and (G6) showed either no staining or very minimal, signifying effective bacterial suppression. As shown in Figures 2 and 3.

Liver sections (IHC)




Fig. (2). liver sections in all experimental groups by (IHC)




Fig. (3). Intestinal sections in all experimental groups by (IHC)

Growth Performance parameters:

Table (4). Growth performance of *C. perfringens* infected and treated chickens at 21th and 28th days old (M $\pm$ SE), (n=5). Different letters in the same row indicate significant changes.

Groups Parameters	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15 th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
Initial Body weight (gm)	14 th day	646.67 $\pm$ 3.26 ^b	635.28 $\pm$ 4.01 ^b	710.72 $\pm$ 4.42 ^a	653.33 $\pm$ 2.98 ^b	638.33 $\pm$ 3.56 ^b	696.67 $\pm$ 4.36 ^a
Body weight (gm)	21 th day	1021.67 $\pm$ 1.67 ^b	751.67 $\pm$ 6.01 ^f	1310.32 $\pm$ 3.56 ^a	823.33 $\pm$ 4.41 ^c	910 $\pm$ 5.77 ^d	946.67 $\pm$ 6.01 ^c
	28 th day	1531.67 $\pm$ 6.01 ^b	965 $\pm$ 2.89 ^c	1980.00 $\pm$ 1.67 ^a	1090 $\pm$ 5.77 ^d	1315 $\pm$ 2.89 ^c	1313.33 $\pm$ 12.02 ^c
Body weight gain (gm)	21 th day	375 $\pm$ 8.66 ^b	116.39 $\pm$ 1.67 ^c	599.6 $\pm$ 1.65 ^a	170 $\pm$ 5.77 ^d	271.67 $\pm$ 1.67 ^c	255 $\pm$ 2.89 ^c
	28 th day	510.67 $\pm$ 6.01 ^b	213.37 $\pm$ 6.01 ^c	669.68 $\pm$ 2.69 ^a	266.67 $\pm$ 2.89 ^d	405 $\pm$ 8.82 ^c	396.67 $\pm$ 6.01 ^c
Food consumption (gm)	21 th day	530 $\pm$ 5.77 ^b	260 $\pm$ 11.55 ^c	670 $\pm$ 5.77 ^a	283.33 $\pm$ 8.82 ^d	430 $\pm$ 11.55 ^c	423.33 $\pm$ 14.53 ^c
	28 th day	890 $\pm$ 11.55 ^b	450 $\pm$ 11.55 ^c	1150 $\pm$ 11.55 ^a	533.33 $\pm$ 8.82 ^d	766.67 $\pm$ 8.82 ^c	770 $\pm$ 11.55 ^c
Food conversion ratio (FCR)	21 th day	1.41 $\pm$ 0.01 ^d	2.23 $\pm$ 0.05 ^a	1.12 $\pm$ 0.09 ^c	1.67 $\pm$ 0.06 ^b	1.58 $\pm$ 0.01 ^c	1.69 $\pm$ 0.02 ^b
	28 th day	1.75 $\pm$ 0.03 ^c	2.11 $\pm$ 0.04 ^a	1.72 $\pm$ 0.19 ^c	2.00 $\pm$ 0.03 ^b	1.89 $\pm$ 0.04 ^d	1.94 $\pm$ 0.02 ^c

Table (5). Erythrogram of *C. perfringens* infected and treated chickens at 21th and 28th days old (M ± SE), (n=5). Different letters in the same raw indicate significant changes.

Groups	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15 th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
Parameters							
Hb (g/dl)	21 th day	8.6 ± 0.03 ^{ab}	6.53 ± 0.05 ^d	9.10 ± 0.03 ^a	7.98 ± 0.019 ^c	7.49 ± 0.039 ^c	8.33 ± 0.06 ^b
	28 th day	9.18 ± 0.40 ^a	6.22 ± 0.30 ^c	9.70 ± 0.04 ^a	8.38 ± 0.05 ^b	8.44 ± 0.08 ^b	8.87 ± 0.05 ^b
RBCs (10⁶/μl)	21 th day	2.40 ± 0.04 ^a	1.87 ± 0.06 ^c	2.38 ± 0.04 ^a	2.01 ± 0.01 ^b	2.13 ± 0.02 ^{ab}	2.22 ± 0.01 ^{ab}
	28 th day	2.56 ± 0.05 ^a	1.76 ± 0.04 ^b	2.21 ± 0.04 ^a	2.17 ± 0.03 ^a	2.32 ± 0.04 ^a	2.49 ± 0.03 ^a
PCV (%)	21 th day	34.64 ± 0.53 ^a	28.75 ± 0.12 ^d	34.61 ± 0.53 ^a	32.42 ± 0.10 ^c	31.26 ± 0.24 ^c	33.56 ± 0.21 ^b
	28 th day	35.53 ± 0.25 ^a	27.09 ± 0.38 ^c	35.50 ± 0.24 ^a	33.79 ± 0.26 ^b	32.07 ± 0.23 ^b	35.33 ± 0.28 ^a
MCV (fL)	21 th day	144.33 ± 2.10 ^b	153.74 ± 2.80 ^a	145.42 ± 2.20 ^b	158.29 ± 2.30 ^a	146.76 ± 2.40 ^b	151.17 ± 2.70 ^{ab}
	28 th day	138.79 ± 2.50 ^c	153.92 ± 2.40 ^{ab}	161.63 ± 2.90 ^a	155.71 ± 2.20 ^{ab}	138.23 ± 2.60 ^c	141.89 ± 2.80 ^b
MCH (pg)	21 th day	36.66 ± 1.13 ^a	37.40 ± 0.96 ^a	36.60 ± 1.13 ^a	37.29 ± 0.40 ^a	37.39 ± 0.63 ^a	37.21 ± 0.5 ^a
	28 th day	35.92 ± 0.62 ^b	37.10 ± 0.86 ^a	35.85 ± 0.62 ^b	35.25 ± 0.50 ^b	36.17 ± 0.80 ^b	35.04 ± 0.30 ^b
MCHC (g/dL)	21 th day	25.60 ± 0.109 ^a	23.80 ± 0.089 ^c	26.01 ± 0.11 ^a	24.70 ± 0.0198 ^b	24.01 ± 0.099 ^{bc}	24.39 ± 0.025 ^b
	28 th day	25.69 ± 0.11 ^a	23.97 ± 0.25 ^c	26.25 ± 0.11 ^a	24.73 ± 0.26 ^{bc}	24.90 ± 0.21 ^{bc}	25.12 ± 0.11 ^b

Table (6). Leukogram of *C. perfringens* infected and treated chickens at 21th and 28th days old (M ± SE), (n=5). Different letters in the same raw indicate significant changes.

Groups Parameters	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
WBCS (10³ /μl)	21 th day	20.19 ±1.12 ^d	25.41 ±1.53 ^a	20.34 ±1.13 ^d	21.97 ±1.41 ^c	22.34 ±1.44 ^b	20.48 ±1.11 ^d
	28 th day	19.46 ±1.13 ^d	25.75 ±1.46 ^a	19.42 ±1.16 ^c	21.89 ±1.13 ^c	22.02 ±1.18 ^b	19.43 ±1.14 ^c
Heterophils (10³ /μl)	21 th day	4.42 ± 0.05 ^c	8.46 ±0.19 ^a	3.98 ± 0.05 ^d	6.26 ± 0.44 ^b	6.85 0.05 ^b	4.75 ± 0.36 ^c
	28 th day	4.32 ± 0.05 ^c	8.54 ± 0.20 ^a	3.39 ± 0.05 ^d	6.42 ± 0.44 ^b	7.08 ± 0.35 ^b	4.27 ±0.05 ^c
Lymphocytes (10³ /μl)	21 th day	11.22 ±0.12 ^a	9.19 ±0.11 ^c	11.73 ±0.02 ^a	10.88 ±0.11 ^b	10.56 ±0.11 ^b	11.02 ±0.08 ^{ab}
	28 th day	11.19 ± 0.12 ^a	9.24 ± 0.12 ^c	11.99 ± 0.01 ^a	10.92 ± 0.11 ^b	10.38 ± 0.10 ^b	11.07 ± 0.07 ^{ab}
Monocytes (10³ /μl)	21 th day	2.92 ±0.01 ^c	3.95 ± 0.138 ^a	2.86 ± 0.02 ^c	3.17 0.027 ^b	3.19 0.036 ^b	3.03 ± 0.03 ^{bc}
	28 th day	2.26 ± 0.01 ^c	3.63 ± 0.09 ^a	2.20 ± 0.01 ^c	2.82 ± 0.02 ^b	2.75 ± 0.02 ^b	2.35 ± 0.02 ^{bc}
Eosinophils (10³ /μl)	21 th day	1.05 ± 0.01 ^a	1.07 ± 0.01 ^a	1.14 ± 0.01 ^a	1.10 ± 0.01 ^a	1.13 ± 0.01 ^a	1.09 ± 0.01 ^a
	28 th day	1.06 ± 0.01 ^a	1.08 ± 0.01 ^a	1.18 ± 0.01 ^a	1.12 ± 0.01 ^a	1.19 ± 0.01 ^a	1.11 ± 0.01 ^a
Basophils (10³ /μl)	21 th day	0.58 ± 0.01 ^a	0.56 ± 0.02 ^a	0.63 ± 0.02 ^a	0.56 ± 0.03 ^a	0.61 ± 0.01 ^a	0.59 ± 0.01 ^a
	28 th day	0.63 ± 0.02 ^a	0.60 ±0.01 ^a	0.656 ± 0.016 ^a	0.61 ± 0.011 ^a	0.62 ± 0.012 ^a	0.63 ±0.013 ^a

Biochemical study:**Table (7).** Biochemical parameters (liver and kidney functions, and cortisol) of *C. perfringens* infected and treated chickens at 21th and 28th days old (M $\pm$ SE), (n=5). Different letters in the same raw indicate significant changes.

Groups Parameters	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15 th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
AST (U/L)	21 th day	47.73 $\pm$ 1.72 ^d	84.89 $\pm$ 1.99 ^a	45.28 $\pm$ 1.76 ^c	71.34 $\pm$ 2.53 ^b	73.04 $\pm$ 1.16 ^b	65.84 $\pm$ 2.27 ^c
	28 th day	46.25 $\pm$ 1.02 ^d	89.45 $\pm$ 1.87 ^a	41.33 $\pm$ 1.05 ^c	60.17 $\pm$ 0.86 ^b	63.45 $\pm$ 1.66 ^b	55.51 $\pm$ 1.10 ^c
ALT (U/L)	21 th day	9.17 $\pm$ 0.20 ^d	20.12 $\pm$ 0.46 ^a	7.48 $\pm$ 0.21 ^c	15.74 $\pm$ 0.245 ^c	16.48 $\pm$ 0.22 ^b	13.07 $\pm$ 0.138 ^d
	28 th day	9.12 $\pm$ 0.27 ^c	21.82 $\pm$ 0.30 ^a	7.08 $\pm$ 0.27 ^d	11.95 $\pm$ 0.216 ^b	12.62 $\pm$ 0.165 ^b	9.62 $\pm$ 0.30 ^c
ALP (IU/L)	21 th day	52.09 $\pm$ 0.19 ^d	90.69 $\pm$ 0.22 ^a	50.23 $\pm$ 0.20 ^c	73.84 $\pm$ 0.86 ^b	75.53 $\pm$ 0.16 ^b	62.08 $\pm$ 1.21 ^c
	28 th day	52.59 $\pm$ 0.24 ^c	91.51 $\pm$ 1.54 ^a	49.41 $\pm$ 0.23 ^d	62.47 $\pm$ 1.59 ^b	64.67 $\pm$ 1.30 ^b	53.87 $\pm$ 1.05 ^c
Total protein (g/ dL)	21 th day	4.22 $\pm$ 0.0198 ^a	2.91 $\pm$ 0.029 ^c	4.44 $\pm$ 0.02 ^a	4.04 $\pm$ 0.029 ^b	4.09 $\pm$ 0.01 ^b	4.13 $\pm$ 0.01 ^{ab}
	28 th day	4.52 $\pm$ 0.10 ^a	2.69 $\pm$ 0.02 ^c	4.56 $\pm$ 0.012 ^a	4.37 $\pm$ 0.09 ^b	4.29 $\pm$ 0.02 ^b	4.45 $\pm$ 0.01 ^a
Albumin (g/dL)	21 th day	1.50 $\pm$ 0.05 ^a	1.15 $\pm$ 0.06 ^c	1.52 $\pm$ 0.04 ^a	1.43 $\pm$ 0.05 ^b	1.47 $\pm$ 0.03 ^b	1.51 $\pm$ 0.05 ^a
	28 th day	1.59 $\pm$ 0.05 ^a	1.07 $\pm$ 0.06 ^b	1.61 $\pm$ 0.04 ^a	1.51 $\pm$ 0.05 ^a	1.54 $\pm$ 0.04 ^a	1.57 $\pm$ 0.05 ^a
Uric Acid (mg/ dL)	21 th day	7.40 $\pm$ 0.40 ^c	11.60 $\pm$ 0.35 ^a	7.35 $\pm$ 0.38 ^c	9.52 $\pm$ 0.37 ^c	10.34 $\pm$ 0.38 ^b	8.48 $\pm$ 0.37 ^d
	28 th day	8.00 $\pm$ 0.40 ^d	11.70 $\pm$ 0.43 ^a	7.03 $\pm$ 0.35 ^c	9.08 $\pm$ 0.36 ^c	9.11 $\pm$ 0.37 ^b	8.03 $\pm$ 0.37 ^d
Creatinine (mg dL)	21 th day	0.25 $\pm$ 0.02 ^c	0.76 $\pm$ 0.02 ^a	0.20 $\pm$ 0.02 ^c	0.44 $\pm$ 0.01 ^c	0.56 $\pm$ 0.02 ^b	0.35 $\pm$ 0.02 ^d
	28 th day	0.23 $\pm$ 0.02 ^d	0.87 $\pm$ 0.02 ^a	0.17 $\pm$ 0.01 ^c	0.36 $\pm$ 0.02 ^c	0.51 $\pm$ 0.02 ^b	0.25 $\pm$ 0.02 ^d
Cortisol (ng/ml)	21 th day	1.82 $\pm$ 0.22 ^c	3.85 $\pm$ 0.22 ^a	1.80 $\pm$ 0.19 ^c	2.79 $\pm$ 0.206 ^c	2.84 $\pm$ 0.20 ^b	2.39 $\pm$ 0.18 ^d
	28 th day	1.90 $\pm$ 0.20 ^c	3.92 $\pm$ 0.21 ^a	1.78 $\pm$ 0.09 ^d	2.41 $\pm$ 0.20 ^b	2.49 $\pm$ 0.20 ^b	1.92 $\pm$ 0.19 ^c

Antioxidants status:**Table (8).** Antioxidants status of *C. perfringens* infected and treated chickens at 21th and 28th days old (M ± SE), (n=5). Different letters in the same raw indicate significant changes.

Groups Parameters	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15 th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
SOD (u/ml)	21 th day	530.0 ± 4.97 ^b	350.0 ± 4.72 ^f	572.2 ± 4.81 ^a	428.4 ± 5.11 ^d	405.1 ± 5.22 ^c	460.2 ± 5.4 ^c
	28 th day	540.0 ± 4.72 ^b	341.0 ± 4.60 ^e	610.0 ± 4.61 ^a	485.2 ± 4.84 ^d	465.0 ± 5.12 ^d	524.5 ± 5.01 ^{bc}
CAT (u/ml)	21 th day	21.4 ± 1.34 ^b	14.31 ± 1.02 ^f	23.5 ± 1.21 ^a	16.3 ± 1.11 ^d	15.4 ± 1.40 ^c	18.5 ± 1.22 ^c
	28 th day	21.0 ± 1.12 ^b	13.13 ± 0.90 ^d	24.4 ± 1.00 ^a	19.1 ± 1.00 ^c	18.7 ± 1.34 ^c	20.5 ± 1.11 ^b
MDA (mmol/l)	21 th day	9.1 ± 0.30 ^c	13.6 ± 0.52 ^a	8.62 ± 0.33 ^c	11.2 ± 0.50 ^c	12.5 ± 0.41 ^b	10.5 ± 0.44 ^d
	28 th day	9.0 ± 0.24 ^c	14.3 ± 0.40 ^a	8.31 ± 0.42 ^d	10.0 ± 0.32 ^b	10.4 ± 0.31 ^b	9.7 ± 0.33 ^c

Some immunological parameters:**Table (9).** Immunological parameters of *C. perfringens*

Groups Parameters	Age of bird	G1 (-ve Control)	G2 <i>C. perfringens</i> (+ve Control)	G3 <i>B. licheniformis</i> alone from day one	G4 <i>B. licheniformis</i> from day one + <i>C. perfringens</i> at 15 th day	G5 Infected with <i>C. perfringens</i> + Bacitracin Zn after infection	G6 Infected with <i>C. perfringens</i> + <i>B. licheniformis</i> from day one + Bacitracin Zn after infection
Phagocytic %	21 th day	75.04 ± 1.30 ^b	37.08 ± 0.71 ^f	79.44 ± 1.35 ^a	65.49 ± 1.17 ^d	61.77 ± 1.26 ^c	68.82 ± 2.00 ^c
	28 th day	76.0 ± 0.96 ^b	41.2 ± 0.73 ^c	81.2 ± 1.01 ^a	69.09 ± 1.17 ^d	67.91 ± 1.27 ^d	75.30 ± 1.43 ^{bc}
Phagocytic Index	21 th day	4.53 ± 0.13 ^a	1.03 ± 0.72 ^c	4.64 ± 0.13 ^a	3.19 ± 0.12 ^c	2.82 ± 0.14 ^d	3.79 ± 0.14 ^b
	28 th day	4.46 ± 0.17 ^b	1.83 ± 0.11 ^d	4.98 ± 0.18 ^a	3.14 ± 0.07 ^c	3.04 ± 0.17 ^c	4.40 ± 0.14 ^b
IgG (mg/dL)	21 th day	911 ± 2.12 ^d	953 ± 3.22 ^a	913 ± 1.73 ^d	937.80 ± 2.26 ^b	936.44 ± 1.42 ^b	924.40 ± 1.41 ^c
	28 th day	920 ± 2.0 ^d	960 ± 3.51 ^a	926 ± 1.99 ^d	944.4 ± 1.58 ^b	941.3 ± 2.02 ^b	915.9 ± 1.99 ^{cd}

Discussion

This study demonstrated that *C. perfringens* type A is the primary agent responsible for NE in broilers, with alpha-toxin being central to disease severity. Infections in animals are associated with particular types of toxins produced by *C. perfringens*, indicating that variations in toxin production influence the virulence traits of the pathogen's isolates. (Petit *et al.*, 1999). The genes *cpa* and *cpb*, which are involved in the pathogenicity of *C. perfringens* to produce NE, and the toxin expressed on the plasmid (Albini *et al.*, 2007). The primary toxins generated by strains of *C. perfringens* are A, B, C, and I. (Prabhu *et al.*, 2013; and Abd Al-Tawab *et al.*, 2014). *Clostridium perfringens* type A is the main culprit which responsible to both clinical and subclinical NE in chickens and found in the environment and in the intestines of warm-blooded animals (Songer and Meer 1996; Van Immerseel *et al.*, 2004). The ability of *C. perfringens* strains to induce gas gangrene arises from their production of α -toxin, which is the only significant typing toxin generated by type A strains. (Awad *et al.*, 1995, Songer, 1996 and Rood, 2007). Our findings, which are consistent with those of Wages (2003), Keyburn *et al.* (2010), Yang *et al.* (2021), and Sally *et al.* (2023), who proposed that the primary virulence factor for NE lesions found during an outbreak is alpha toxin showed an increase in toxin in both *cpa* and *cpb* gene expression, particularly in experimental groups as compared to normal control ones. In the current study's antimicrobial sensitivity profiling to 14 antibiotics of verified *C. perfringens* isolates Type A were Bacitracin Zn which showed strong antibacterial activity against *Clostridium perfringens*, followed by lincomycin, ceftriaxone, vancomycin, enrofloxacin, ciprofloxacin, ampicillin, clindamycin, tiamulin, amoxicillin, metronidazole, rifampicin and tylosin. The most promising four antibiotic medications were Bacitracin Zn, Enrofloxacin, Lincomycin, and Clindamycin examined for MIC and MBC; Bacitracin Zn showed the highest rates of sensitivity.

The IHC findings from this study align with the established pathology of necrotic enteritis, and the detection of brown deposits in both liver and intestinal tissues verifies the presence

of *C. perfringens* alpha-toxin. Treatment with Bacitracin Zn (G5) and the combination of GalliproTect® with Bacitracin Zn (G6) demonstrated a lower presence of toxins when compared to the positive control, indicating a potential protective or therapeutic role. These results align with (Costa *et al.*, 2018; Ritter *et al.*, 2019 and Lin *et al.*, 2013) Who attributed this reduction due to the effect of GalliproTect® as probiotic which act as growth promoters and the main line of defense against *C. perfringens* because of their ability to prevent infection, change the gut microbiota, reduce inflammation in the gastrointestinal tract and improve GIT health. This prevents the bacterial colonies from being washed away by the peristalses of the intestinal wall because they adhere to the wall and prevent pathogenic germs from colonizing the gut wall, which stops the disease from progressing. These results endorse the application of IHC as an additional diagnostic method and emphasize the effectiveness of the treatment protocols. (Meer and Songer, 1997; Kadra *et al.*, 1999 and Wu *et al.*, 2009). The reduction in immunostaining in G5 and G6 highlights the therapeutic effectiveness of Bacitracin Zn, either alone or in combination with GalliproTect®. These findings are consistent with previous studies that demonstrated reduced necrotic enteritis severity following probiotic or antibiotic administration (Knarreborg *et al.*, 2002). IHC remains a critical technique to validate infection control in histological samples.

The performance characteristics regarding growth in broiler chickens during the starter, grower (pre-infection), and finisher stages (post-infection) were analyzed. When comparing the groups that had probiotics in their drinking water, there was a notable increase in body weight (BW), body weight gain (BWG), and feed conversion ratio (FCR) compared to the other experimental groups, except for the broilers that were given GalliproTect® in their drinking water from day one, all the other experimental groups showed significant growth retardation at the end of the *C. perfringens* challenge in relation to the control positive group. These results align with those of Kabir *et al.* (2004), Li *et al.* (2010), and Zhou *et al.* (2016), who claimed that probiotic supplement-

tation can improve chicken performance. The results clearly show that the experimental birds' live weight gains were substantially ($P < 0.05$) higher than those of the control group. Moreover, probiotics enhance feed conversion efficiency via several mechanisms, including alterations in intestinal flora, promotion of gram-positive and nonpathogenic facultative anaerobic bacteria that generate hydrogen peroxide and lactic acid, suppression of intestinal pathogen development, and better digestion and utilization of nutrients. (Villagr n-de la Mora *et al.*, 2020; Elleithy *et al.*, 2023 and Garc a-Vela *et al.*, 2023 (.Abudabos *et al.* (2017) and Xue *et al.* (2018) ascribed that to its involvement in necrotic enteritis, which damages intestinal function, impairs nutrient absorption, and negatively affects growth performance by destroying gut integrity, lowering villus height, and activating the immune system.

Changes in hematological parameters in broilers with necrotic enteritis may be caused by a bacterial toxin. Our results showed that broilers infected with *C. perfringens* showed a significant decrease in hemoglobin concentration and RBC count. A decrease in the erythrogram was also seen, which may be related to intravascular hemolysis brought on by *C. perfringens* (El-Deen *et al.*, 2019); Allam *et al.*, (2013). According to Kojima *et al.* (2023) and Charitaki and Liapis (2025), Clostridial toxins facilitate the breakdown of phospholipids in erythrocyte membranes, leading to hemolysis by damaging the circulating red blood cells. Total leukocyte count, heterophil, and monocyte levels were assessed, but lymphocyte levels significantly decreased in the infected group. The groups treated for the infection exhibited a notable rise in RBC count and hemoglobin content compared to the untreated infected group. Based on the findings of Nagaralli *et al.* (2002). Bacitracin ZN hinders the production of cell wall mucopeptides during the multiplication of bacteria. Mikkelsen *et al.* (2009) observed that the incorporation of organic acids inhibited the proliferation of *C. perfringens*. Our results align with those of El-Gharbawy (2014), Sayed *et al.* (2016), and Sally *et al.* (2023) who found an enhancement in erythrogram parameters in broilers infected with *C. perfringens*. The variations in leu-

kograms identified in our research may be associated with bacterial infections and inflammation, resulting in leukocytosis, heterophilia, and monocytosis. (Nasr El-Deen *et al.* 2019). Our findings were consistent with those of Gheith *et al.* (2011) and Saleh *et al.* (2011), who revealed leukocytosis and heterophilia as characteristics of *C. Perfringens* infected broilers. The leukograms of birds treated with Bcitracin Zn or GalliproTect , or a combination of Bcitracin Zn and GalliproTect , improved when compared to the non-treated group. (El-Shahat ,2014 and El-Sheikh *et al.*, 2018) reported similar findings. Probiotics have demonstrated their ability to enhance the immune system through several mechanisms, such as increased lymphocyte levels, oxidative bursts in heterophils, and the production of immunoglobulins by soothing the digestive tract and modulating the immune response, probiotics may assist in preserving a proper equilibrium between pro-inflammatory and anti-inflammatory cytokines. (Shumaila *et al.*, 2022).

The treated groups had significantly lower levels of AST, ALT, ALP, total protein, albumin, uric acid, creatinine, and cortisol than the positive control group. Serum total protein levels in the treatment groups were significantly higher than those in the control positive group. The majority of the measures listed below reverted to normal in the treated groups when compared to the control negative group. An increase in liver enzyme levels (AST and ALT) was noted in the *C. perfringens* infected group, suggesting biliary stasis and liver damage brought on by clostridial toxins. (El-Deen *et al.*,2019). Serum levels of uric acid and creatinine were significantly increased in the untreated infected group, which may suggest renal damage and cellular death. The deterioration of renal tubules impaired the excretion of uric acid and creatinine, resulting in higher serum levels of these substances in the infected birds. Similar findings were noted by Allam *et al.* (2013), El-Deen *et al.* (2019), Sally *et al.* (2023), and Saleh *et al.* (2023). Hypoproteinemia observed in the infected non-treated group may be due to reduced feed consumption, excretion through the colon and kidneys, or liver damage caused by clostridial toxins. An increase in probiotic levels in broilers led to a significant rise in

blood uric acid levels. Additionally, cortisol levels in the blood were elevated in the infected group compared to the control group as a consequence of *C. perfringens* infection, which can have a cytotoxic impact at high concentrations, resulting in nuclear fragmentation and damage to genetic material. (Zhang *et al.*, 2017). Considering this, our results aligned with the observations of Zaytsoff *et al.* (2020), who discovered changes in cortisol levels associated with *C. perfringens* infection in chickens as a physiological response to stress.

Oxidative stress is currently a significant issue in animal production across the globe. (Sies and others, 2017). CAT and SOD levels in treatment groups were significantly lower than those in the control positive group, indicating a decline in antioxidant status. In contrast to the control positive group, MDA significantly increased in the treatment groups. When compared to the negative control group, the majority of the markers showed reverted to normal ranges in the treated groups. This is consistent with the findings of Surai *et al.* (2019), who found that most stress, regardless of its cause, is associated with an imbalance in the formation of free radicals and detoxification. Additionally, *B. licheniformis* has the ability to safeguard hens from oxidative harm by managing the redox balance of the host through mechanisms such as metal ion chelation, antioxidant enzymatic activity, regulatory signaling pathways, and the modulation of gut microbiota. (Zhang *et al.*, 2017; Zhao *et al.*, 2020). In contrast, Lei *et al.* (2013) showed that treatment with *B. licheniformis* does not influence the activity of antioxidant enzymes in laying hens, except for glutathione S-transferase (GST). This might be related to the role of *B. licheniformis*, which could vary based on strain and dietary concentration. Furthermore, Pereira (2014) and Darafsh *et al.* (2020) found a reduction in the activity of glutathione peroxidase, superoxide dismutase, and catalase following the administration of probiotics.

The obtained immunological results, it was obvious the decline in phagocytic activity, accompanied with an elevation in IgG as a conse-

quence of *C. perfringens* infection. Our results reinforced previous results of Salah *et al.* (2015); El-Deen *et al.* (2019) who expressed that IgG significantly increased in *C. Perfringens*. Additionally, *B. licheniformis* supplement significantly promoted the thymus index and spleen index, and the bursa index at different dosage and period, and these immune organ index reflects the immune function of the body (Qin *et al.*, 2024). These findings all proved that *Bacillus* has a beneficial impact on enhancing immunological function. While, phagocytic percentage and phagocytic index were decreased. However, administration of bacitracin zn and/or GalliproTect® effectively improved the immunological parameters. These results were in harmony with those of Kan *et al.* (2021) and Abou-Khadra *et al.*, (2024), who documented that treatments with antibiotic or probiotic or both could ameliorate the immunity in clostridial infection. Our study showed that, when compared to the control group, the inclusion of GalliproTect® significantly increased the phagocytic percentage, phagocytic index, and IgG levels.. Similarly, numerous studies Darafsh *et al.*, (2018); Pan *et al.*, (2022) who record a gradual increase in IgG levels due to *B. licheniformis* treatment, and Elleithy *et al.*, (2023) Numerous studies show that probiotics clearly enhance the immune system, helping the body fight off harmful organisms. This effect may be linked to the fact that *Bacillus* has a cell barrier composed of dextran, which acts as an immunostimulant. (Abdelqader *et al.*, 2013).

Conclusion

The study's findings demonstrate that *C. perfringens* can cause disease in broiler chickens and has a major effect on the productivity and well-being of the birds. By administering GalliproTect® alone or in combination with Bacitracin Zn, the severity of necrotic enteritis is lessened, growth performance is improved, immunological responses are improved, and antioxidant status is improved while the infection severity is decreased. Furthermore, the presence of bacterial toxins in intestine and liver tissues was confirmed by immunohistochemistry (IHC), and Real Time PCR has been shown to be a successful technique for detecting toxin genes. With regard to avoiding and

managing necrotic enteritis in chicken husbandry, these findings collectively support the use of probiotics as a sustainable substitute or adjunct to antibiotics.

Acknowledgment

The authors express deep gratitude to Dr. Tharwat Ibrahim Ahmed, Chief Researcher of Pathology, Animal Health Research Institute, Zagazig, for his valuable support.

References

- Abebi, H. (1974).** Catalase. Methods in Enzymatic. Analysis. Academic Press, New York, 2: 674-684.
- Abd Al-Fatah, M. (2020).** Probiotic Modes of Action and Its Effect on Biochemical Parameters and Growth Performance in Poultry. Iranian Journal of Applied Animal Science, 10(1): 9-15.
- Abd Al-Tawab, A.A.; El-Hofy-Fatma, I.; Khater-Dalia, F. and Kotb, M.M. (2015).** "Typing of *Clostridium perfringens* isolated from some meat products by using PCR". Benha Vet. Med. J., 29(1):118-123.
- Abd El-Hack, M.E.; El-Saadony, M.T.; Salem H.M.; El-Tahan, A.M.; Soliman, M.M.; Youssef, G.B.A.; Taha, A.E.; Soliman, S.M.; Ahmed, A.E.; El-kott, A.F.; Al Syaad, Kh.M. and Swelum, A.A. (2022).** Alternatives to antibiotics for organic poultry production : types, modes of action and impacts on bird's health and production. Poultry Science Volume 101, Issue 101696.
- Abudabos, A.M.; Alyemni, A.H.; Dafalla, Y.M. and Khan, R.U. (2017).** The effect of phytogenics on growth traits, blood biochemical and intestinal histology in broiler chickens exposed to *Clostridium perfringens* challenge. J. Appl. Anim. Res. 46, 691–695.
- Abdelqader, A.; Irshaid, R. and Al-Fataftah, A.R. (2013).** Effects of dietary probiotic inclusion on performance, eggshell quality, cecal microflora composition, and tibia traits of laying hens in the late phase of production. Trop Anim Health Prod. 45:1017–24.
- Additives, E.P.O.; Feed, S.U.I.; Bampidis, A.; Azimonti, V.; Bastos, G.; Christensen, M.D.L.; Dusemund, H.; Durjava, B.; Kouba, M.; Lopez-Alonso, M. and Lopez Puente, S. (2023).** Safety and efficacy of the feed additive consisting of protease produced by *Bacillus licheniformis* DSM33099 (ProAct360) for use in poultry species for fattening or reared for laying/breeding (DSM Nutritional Products Ltd). EFSAJ. 21: e08163.
- Abou-Khadra, S.; Hamed, T.; Ewis, H.; Shaltot, S. and Mohamed, D. (2024).** Efficacy of both antibiotic and probiotic for control of necrotic enteritis in chickens experimentally. Egyptian Journal of Animal Health, 4(1), 34-58.
- Alizadeh, M.; Shojadoost, B.; Fletcher, C.H.; Wang, A.; Abdelaziz, K.H. and Sharif, S.H. (2021).** Treatment of chicken with lactobacilli prior to challenge with *C.perfringens* modifies innate responses and gut morphology. Research in Vet.Sci. Volume 172, 105241.
- Albini, S.; Brodard, I.; Jaussi, A.; Wollschlaeger, N.; Frey, J.; Miserez, R. and Abril, C. (2007).** Real-time multiplex PCR assays for reliable detection of *Clostridium perfringens* toxin genes in animal isolates. Vet Microbio 15; 127(1-2):179-85.
- Allam, H.H.; Nahad, A.G.; Abdulla, S.H. and Dina, M.M. (2013).** Immuno- Biochemical and pathological studies on necrotic enteritis in pekin duckling with trial of treatment. J. Mansoura Vet. Med., XV (1): 211-226.
- Awad, M.M. (1995).** Virulence studies on chromosomal a-toxin and T-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of a-toxin in *Clostridium perfringens*-mediated gas-gangrene. Mol. Microbiol. 15, 191-202
- El-Gharbawy, E. (2014).** Concurrent use of amoxicillin and metronidazol for controlling clostridial problems in broiler chickens. M.Sc. 414 S. M. El-Sheikh, M. H. Khairy, N. Z.H. Eleiwa, O. E. Abdalla, A. G. Abd El Monsef Thesis Fac. of Vet Med. (Pharmacology) Monefia University.
- Elleithy, E.M.M.; Bawish, B.M.; Kamel, S.; Ismael, E.; Bashir, D.W.; Hamza, D. and Fahmy, K.N.E. (2023).** Influence of dietary *Bacillus coagulans* and/or *Bacillus licheniformis*-based probiotics on performance, gut health, gene expression, and litter quality of broiler chickens. Trop. Anim. Health Prod. 55 (1), 38.

- Bathhoko, T.D. (2009).** Performance of *Clostridium perfringens* challenged broiler chickens inoculated with effective microorganisms. msc agric. (animal science), faculty of natural and agricultural science, Pretoria Univ. BSAC. Version 10.2. Birmingham, United Kingdom.
- Bassoe, C.F.; Smith, I.; Sørnes, S.; Halstenen, A. and Lehmann, A.K. (2000).** Concurrent measurement of antigen- and antibody-dependent oxidative burst and phagocytosis in monocytes and neutrophils. *Methods* 21: 203–220.
- Butaye, P.; Devriese, L.A. and Haesebrouck, F. (2003).** Anti-microbial growth promoters used in animal feed: effects less well-known antibiotics on gram – positive bacteria. *Clin. Microbial. Rev.*, 16: 175 – 188.
- Caraway, W. (1955).** Colorimetric determination of uric acid with deproteinization. *J Am Clin Path*, 25: 840.
- Cengiz, Ö.; Köksal, B.H.; Tatlı, O.; Sevim, Ö.; Ah-san, U. and Üner, A.G. (2015).** Effect of die-tary probiotic and high stocking density on the performance, carcass yield, gut microflora, and stress indicators of broilers. *Poultry Science*; 94(10):2395-2403.
- Charitaki, E. and Liapis, K. (2025).** Spherocytic hemolytic anemia caused by *Clostridium perfringens*. *Int. J. Hematol.* 03993-3.
- Cheng, Y.H.; Horng, Y.; Dybus, A. and Yu, Y.H. (2020).** *Bacillus licheniformis* Fermented Products Improve Growth Performance and Intestinal Gut Morphology in Broilers under *Clostridium perfringens* Challenge. *The Journal of Poultry Science (jpsa)*, 0200010.
- Chen, Y.C. and Yu, Y.H. (2020).** *Bacillus licheniformis* fermented products improve growth performance and the fecal microbiota community in broilers. *Poult. Sci.* 99: 1432–1443.
- Cooper, K.K. and Songer, J.G. (2009).** Necrotic enteritis in chickens: a paradigm of enteric infection by *Clostridium perfringens*. *Anaerobe*, 15(1-2), 55–60.
- Costa, M.C.; Bessegatto, J.A.; Alfieri, A.A., Weese, J.S.; Filho, J.A. and Oba A. (2017).** Different antibiotic growth promoters induce specific changes in the cecal microbiota membership of broiler chicken PLoS One, 12 (2017), Article e0171642.
- Cruickshank, R.; Duguid, J.P.; Marmion, B.R. and Swain, R.H.A. (1975).** *MED. Microbiol.* Vol.11, 12th ed.
- Darafsh, F.; Soltani, M.; Abdolhay, H.A. and Mehrejan, Sh.M. (2020).** Efficacy of dietary supplementation of *Bacillus licheniformis* and *Bacillus subtilis* probiotics and *Saccharomyces cerevisiae* (yeast) on the hematological, immune response, and biochemical features of Persian sturgeon (*Acipenser persicus*) fingerlings. *Iranian Journal of Fisheries Sciences*, 19(4) 2024-2038.
- Doumas, B.T.; Bayso, D.D.; Carter, R.J.; Peter, T. and Schaffer, R. (1981).** Determination of serum albumin. *Clin Chem*, 27(10): 1642-1650.
- El-Deen, N.A.; Gamal El-Din, I.M. and Khodary, M.R. (2019).** Effect of Experimental *Clostridium perfringens* Infection on Some Immunological, Hematological and Biochemical Values in Broiler Chickens. *Zag. Vet. J.*, 47(2): 222-233.
- El-Shahat, I.E. (2014).** Concurrent use of amoxi-cillin and metronidazole for controlling clostridial infection in broiler chickens. M.V.Sc. Thesis. Pharmacology Department, Faculty of Veterinary Medicine, El-Sadat University.
- El-Sheikh, S.M.; Khairy, M.H.; Eleiwa, N.Z.E.; Osama, E.A. and Abd ElMonsef, A.G. (2018).** Effect of sanguinarine phytobiotic, sodium butyrate compared to ampicillin on controlling necrotic enteritis in broiler chickens. *Slov Vet Res*, 55(20): 405–414.
- ESVAC. (2017).** Sales of veterinary antimicrobial agents in 30 European countries in 2015. Trends from 2010 to 2015. European Medicines Agency, Seventh European Surveillance of Veterinary Antimicrobial Consumption report (EMA/184855/2017).
- Food and Agriculture Organization, (FAO); World Health Organization, (WHO) (2006).** Probiotics in Food Health and Nutritional Properties and Guidelines for Evaluation; FAO, WHO, Eds.; FAO WHO: Rome, Italy, Volume 85, ISBN 9251055130.
- Fridovich, I. (1989).** Superoxide dismutases. An adaptation to a paramagnetic gas. *J. Biol. Chem.* 264: 7761-7764.

- Gheith, I.; Fararh, K.; Bakry, H. and Hosney, G. (2011).** Clinicopathological effect of probiotics on enteric diseases in broiler chicks. *J Benha Vet Med*, 22(2): 25-34.
- Giambrone, J.J. and Ronald, P.E. (1986).** Vaccination of one day old broiler chicks against New Castle and infections bursal disease using commercial live and / or inactivated vaccines . *Avian Dis.*, 30(3): 557-562.
- García-Vela S.; Guay, L.D.; Rahman, M.D.R.T.; Biron, E.; Torres, C. and Fliss, I. (2024).** Antimicrobial Activity of Synthetic Enterocins A, B, P, SEK4, and L50, Alone and in Combinations, against *Clostridium perfringens*. *Int J Mol Sci*. Jan 27; 25(3):1597.
- Grant, G.H.; Silverman, L.M. and Christenson, R.H. (1987).** Aminoacids and proteins. (Fundamental of Clinical Chemistry). 3th WB Saunders Company. edition. Philadelphia: (4)557-562 .
- Han, Y.; Xu, X.; Wang, J.; Cai, H.; Li, D.; Zhang, H.; Yang, P. and Meng, K. (2023).** Dietary *Bacillus licheniformis* shapes the foregut microbiota, improving nutrient digestibility and intestinal health in broiler chickens. *Front. Microbiol.* 14:1113072.
- Hofacre, C.L.; Froyman, R.; George, B.; Goodwin, M.A. and Brown, J. (1998).** Use of Avigaurd and other intestinal bioproducts in experimental *Cl stridium perfringens*-associated necrotizing enteritis in broiler chickens. *J. Appl. Poult. Res.* 7:412-418.
- Husdan, H. and Rapoport, K. (1968).** Chemical determination of creatinine with deproteinization. *Clin Chem*, 14(3): 222-238.
- Janero, D.R. (1990).** Malondialdehyde and thiobarbituric acid reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury . *Free Radic . Bio. Med.*9:515-540.
- Jiang, N.; Yang, W.R.; Gao, Q.X.; Zhang, C.Y.; Liu, F.X. and Sun, X.P. (2013).** Influences of antibiotics on the growth performance and intestinal immunity of Lingnan yellow broilers. *Acta Agriculturae Universitatis Jiangx* 35 (4), 819-825.
- Kabir, S.M.L.; Rahman, M.M.; Rahman, M.B.S.; Rahmau, M.M. and Ahmed, S.U. (2004).** The dynamics of probiotics on growth performance and immune response in broilers. *Int. J. Poult. Sci.* 3:361-364.
- Kadra, B.; Guillou, J.P.; Popoff, M. and Bourlioux, P. (1999).** Typing of sheep clinical isolates and identification of enterotoxigenic *Clostridium perfringens* strains by classical methods and by polymerase chain reaction (PCR). *FEMS Immunol. Med. Microbiol.* 24:259-266.
- Kaldhusdal, M. and Hofshagen, M. (1992).** Barley inclusion and avoparcin supplementation in broiler diets. Effects on performance and health. *Poultry Science*, 71(4), 505–512.
- Kan, L.; Guo, F.; Liu, Y.; Pham, V.H.; Guo, Y. and Wang, Z. (2021).** Probiotics *Bacillus licheniformis* Improves Intestinal Health of Subclinical Necrotic Enteritis-Challenged Broilers. *Front. Microbiol.* 12: 623739.
- Kind, P. and King, E. (1954).** Estimation of plasma phosphatase by determination of hydrolyzed phenol with amino-antipyrine. *J Clin Path*, 7(4): 322–326.
- Keyburn, A.L.; Yan, X.X.; Bannam, T.L.; Van Immerseel, F.; Rood, J.I. and Moore, R.J. (2010).** Association between avian necrotic enteritis and *Clostridium perfringens* strains expressing *netB* toxin. *Vet. Res.* 41:21.
- Kinnear, P. and Gray, C. (2006).** SPSS 12 Made Simple. Psychology, press.
- Kojima, H.; Shimizu, Y. and Sugiyama, K. (2023).** *Clostridium perfringens* bacteremia and intravascular hemolysis, *QJM: An International Journal of Medicine*, 116 (2): 139–140.
- Koneman, E.W.; Allen, S.D.; Dowell, V.R. and Summers, H.W. (1992).** Colour atlas and text book of diagnostic microbiology. 4th ed Lippin cott JB, New York, London.
- Knarreborg, A.; Simon, M.A.; Engberg, R.M.; Jensen, B.B. and Tannock (2002).** Effects of dietary fat source and subtherapeutic levels of antibiotic on the bacterial community in the ileum of broiler chickens at various ages. *Applied and Environmental Microbiology*, 68(12), 5918–5924.
- Lei, K.; Li, Y.L.; Yu, D.Y.; Rajput, I.R. and Li, W.F. (2013).** Influence of dietary inclusion of *Bacillus licheniformis* on laying performance, egg quality, antioxidant enzyme activities, and intestinal barrier function of laying hens. *Poult. Sci.* 92:2389–95.
- Lin, J.; Hunkapiller, A.A.; Layton, A.C.; Chang, Y.J. and Robbins, K.R. (2013).** Re-

- sponse of intestinal microbiota to antibiotic growth promoters in chickens Foodborne Pathog Dis, 10 , pp. 331-337 .
- Liu, D.; Guo, Y.; Wang, Z. and Yuan, J. (2010).** Exoge-nous lysozyme influences *Clostridium perfringens* colonization and intestinal barrier function in broiler chickens. *Avi-an Pathol.* (39): 17–24. 47. Doxy D. Clinical pathology and diagnostic procedure 2 nd Ed. Baillier London.1983; 56–60.
- Loriaux, D.L. (2017).** Diagnosis and differential diagnosis of Cushing's syndrome. *N Engl J Med* ; 376: 1451-9.
- Lovland, A.; Kaldhusdal, M. and Reitan, L.J. (2003).** Diagnosing *Clostridium perfringens*-associated necrotic enteritis in broiler flocks by an immunoglobulin G anti-alpha-toxin enzyme-linked immunosorbent assay. *Avian Pathol*, 32(5): 527-534.
- Lyras, D.; O'Connor, J.R.; Howarth, P.M.; Sambol, S.P.; Carter, G.P.; Phumoonna, T. and Rood, J.I. (2009).** Toxin B is essential for virulence of *Clostridium difficile*. *Nature*, 458(7242): 1176-1179.
- Martel, A.; Devriese, L.A.; Cauwerts, K.; De-Gussem, K.; Decostere, A. and Haesebrouck, F. (2004).** Susceptibility of *Clostridium perfringens* IIS strains from broiler chickens to antibiotics and anticoc-cidials. *Avian Pathol.*, 31: 3–7.
- Meer, R.R. and Songer, J.G. (1997).** Multi-plex polymerase chain reaction assay for genotyping *Clostridium perfringens*. *Am. J. Vet. Res.* 58:702-705.
- Mikkelsen, L.L.; Vidanarachchi, J.K.; Olnood, C.G.; Bao, Y.M.; Selle, P.H. and Choct, M. (2009).** Effect of potassium difor-mate on growth performance and gut micro-biota in broiler chickens challenged with ne-crot-ic enteritis. *Br Poult Sci*, 50(1): 66–75.
- M'Sadeq, S.A.; Wu, S.; Swick, R.A. and Choct, M. (2015).** Towards the control of necrotic enteritis in broiler chickens with in-feed antibiotics phasing-out worldwide. *Animal Nutrition* 1(1): 1-11.
- Nagaralli, B.; Seetharamappa, J. and Melwanki, M. (2002).** Sensitive spectropho-tometric methods for the determination of amoxicillin, ciprofloxacin and piroxicam in pure and pharmaceutical formulations. *J Pharma Biomed Anal*, 29(5): 859-864.
- National Committee for Clinical La-boratory Standards (2004).** Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard - 6th edition. NCCLS Document M11-A6, Vol. 24 N° 2. NCCLS, Wayne, PA. Percy D.H., Muckle C.A., Hampson R.J., Brash.
- Oberley, L.W. and Spitz, D.R. (1985).** Assay of Superoxide Dismutase Using Nitroblue Tetrazolium. In: Greenwald, R.A., Ed., Handbook of Methods for Oxygen Radical Research, CRC Press, Boca Raton, 217-221.
- Osman, K.M. and Elhariri, M. (2013).** Antibiotic resistance of *Clostridium perfringens* isolates from broiler chickens in Egypt. *Rev Sci Tech.* 32(3):841-50.
- Pan, X.; Cai, Y.; Kong, L.; Xiao, C.; Zhu, Q. and Song, Z. (2022).** Probiotic Effects of *Bacillus licheniformis* DSM5749 on Growth Performance and Intestinal Microecological Balance of Laying Hens. *Front. Nutr.* 9:868093.
- Pereira, L.F. (2014).** Growth performance, antioxidant and innate immune responses in European seabass fed probiotic supplemented diet at three rearing temperatures. Portugal: Universidade do Porto. Page 53.
- Platt, N. and Fineran, P. (2015).** Chapter 14 - Measuring the phagocytic activity of cells. *Methods in Cell Biology*, 126, 287-304.
- Prabhu, N.K.; Ruban, W.S.; Naveen, B.R. and Raghunath, B.V. (2013).** “Molecular characterization of alpha toxin gene of *Clos-tridium perfringens* from chicken meat”. *J. Cell and Tissue Res.*, 13(1): 3455-3458.
- Qin, S.; Xiao, X.; Dai, Z.; Zhao, G.; Cui, Z.; Wu, Y. and Yang, C. (2024).** Effects of *Ba-cillus licheniformis* on growth performance, immune and antioxidant functions, and intes-tinal microbiota of broilers. *Poultry Science*, 103:103210.
- Reitman, S. and Frankel, F. (1957).** Colori-metric methods for determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases activities. *J Am Clin Path*, 28 (1): 56-63.
- Ritter, G.D.; Acuff, G.R.; Bergeron, G.; Bourassa, M.W.; Chapman, B.J.; Dickso-n, J.S.; Opengart, K.; Salois, M.J.; Singer, R.S. and Storrs, C. (2019).** Antimicrobial-resistant bacterial infections from foods of

- animal origin: understanding and effectively communicating to consumers. *Ann. N. Y. Acad. Sci.*, 1441, pp. 40-49.
- Rood, J.I. (1998).** Virulence genes of *Clostridium perfringens*. *Annu. Rev. Microbiol.* 52, 333-360.
- Rood, J.I. (2007).** *Clostridium perfringens* and histotoxic disease. In *The Prokaryotes: A handbook on the Biology of Bacteria*. Vol 4: Bacteria: Firmicutes, cyanobacteria (3rd edn) (Dworkin, M. *et al.*, eds), pp. 753-770.
- Russell J.B. and Strobel, H.J. (1988).** Effects of additives on In vitro ruminal fermentation: a comparison of monensin and bacitracin, another gram-positive antibiotic. *J Anim Sci.* 66:552-558.
- Salah, H.; Mansour, E.; Reham, R.R. and Abd El Hamid, E.S. (2015).** Study on the effect of humic acid on growth performance, immunological, some blood parameters and control intestinal *Closterdium* in broiler chickens. *Zag Vet J*, 43(1):102-109.
- Saleh, N.; Fathalla, S.I.; Nabil, R. and Mossad, A.A. (2011).** Clinicopathological and immuno-logical studies on toxoids vaccine as a successful alternative in controlling clostridial infection in broilers. *J Anaerobe*, 17 (6): 426-430.
- Saleh, A.A.; Hafez, A.; Amber, K.; Abdelhady, A.Y.; Heba, M.; Salem, H.M.; Fathy, M.; Kamal, M.A.; Alagawany, M. and Alzawqari, M.H. (2023).** Drug-independent control strategy of clostridial infection in broiler chick-ens using anti-toxin environmentally friendly multienzymes, *Scientific Re-ports* (13): 5614.
- Sally, H. Abou-Khadra; Thoria, A. Hamed; Heba, A. Ewis; Shaimaa, H. Shaltot and Dalia, T. Mohamed (2023).** Efficacy of both antibiotic and probiotic for control of necrotic enteritis in chickens experimentally. *Egyptian Journal of Animal Health* 4, 1 (2024), 34-58.
- Sayed, A.; Sabry, M.; Osama, E. and Sarhan, M. (2016).** Concurrent use of ciprofloxacin and metronidazole for controlling of some bacterial infections in broiler chickens. *Benha Vet Med J.*, 2016; 31, (2): 83- 92.
- Senthilkumar, M.; Amaesan, N. and Sankaranarayanan, A. (2021).** Estimation of Catalase. In: *Plant-Microbe Interactions*. Springer Protocols Handbooks. Humana, New York, NY. pp 113-115.
- Shaltout, F.A.; Zakaria, I.M. and Nabil, M.E. (2017).** Detection and typing of *Clostridium perfringens* in some retail chicken meat products. *BENHA VETERINARY MEDICAL JOURNAL*, VOL. 33, NO. 2: 283-291.
- Shumaila, Y.; Hafiz, M.N.; Ibrar, A.; Sabir, H.; Muhammad, W.; Shahid, N.; Muhammad, T.; Ozge, S. and Muhammad, F.Z. Ch. (2022).** A review of probiotic applications in poultry: improving immunity and having beneficial effectson production and health. *postępy mikrobiologii – advancements of microbiology*2022, 61, 3, 115-123.
- Sies, H.; Berndt, C. and Jones, D.P. (2017).** Oxidative stress. *Annual Review of Biochemistry*, 86: 1-34 (doi: 10.1146/annurev-biochem-061516-045037).
- Smith, L.D. and Holdeman, L.V. (1968).** The pathogenic anaerobic bacteria. 1st ed., pp. 201-205, Charles C-Thomas publisher, U.S.A.
- Songer, J.G. (1996).** Clostridial enteric diseases of domestic animals. *Clin. Microbiol. Rev.* 9, 216-234.
- Songer, J.G. and Meer R.R. (1996).** Genotyping of *Clostridium perfringens* by polymerase chain reaction is a useful adjunct to diagnosis of Clostridial enteric disease in animals. *Anaerobe* 2,197-203.
- Star, L.; Frankena, K.; Kemp, B.M.G.; Nieuwland, B. and Parmentier, H.K. (2007).** Natural humoral immune competence and survival in layers. *Poult Sci*, 86(6): 1090-1099.
- Sultan, K. and Abdul-Rahman, S. (2011).** Effect of probiotic on some physiological param-eters in broiler breeders. *Int. J. Poult. Sci.* (10): 626-628.
- Surai, P.F.; Kochish, I.I.; Fisinin, V.I. and Kidd, M.T. (2019).** Antioxidant defence systems and oxidative stress in poultry biology: an update. *Antioxidants*, 8(7): E235 (doi: 10.3390/antiox8070235).
- Thrall, M.A.; Weiser, G.; Allison, R. and Campbell, T. (2012).** *Veterinary Hematology and Clinical Chemistry* (John Wiley Sons, 2012).
- Timbermon, L.; Lanckriet, A.; Gholamian-dehkordi, A.R.; Pasmans, F.; Martel, A.;**

- Haesebrouck, F.; Ducatelle, R. and Immerseel, F.V. (2009).** Origin of *C. perfringens* isolated determines the ability to induce necrotic enteritis in broilers. *Comparative Immunology, Microbiology and Infectious Diseases*. Volume 32, Issue 6, Pages 503-512.
- Uzal, F.A.; Freedman, J.C.; Shrestha, A.; Theoret, J.R.; Garcia, J. and Awad, M.M. (2014).** Towards an understanding of the role of *Clostridium perfringens* toxins in human and animal disease *Fut. Microbiol.*, 9, pp. 361-377.
- Vaikosen, E.S. and Muller, W. (2001).** Evaluating biochemical tests for isolation and identification in *Clostridium perfringens* in fecal samples of small ruminants in Nigeria. *Bull. Anim. Health Prod. Afr.*, 49(4): 244–248.
- Van Immerseel, F.; DeBuck, J.; Pasmans, F.; Huyghebaert, G.; Haesebrouck, F. and Ducatelle, R. (2004).** *Clostridium perfringens* in poultry in an emerging threat for animal and public health. *Avian Pathol.*, 33:537–549.
- Veken, K.V.D.; Willems, S. and Lauwerier, E. (2021).** Health promotion in socially vulnerable youth: Sports as a powerful vehicle? *Health Promotion Practice*, 22(2), 275–286.
- Villagrán-de la Mora, Z.; Macías-Rodríguez, M.E.J.A.Q.; Gonzalez-Torres, Y.S.; Nuño, K. and Villarruel-López, A. (2020).** *Clostridium perfringens* as Foodborne Pathogen in Broiler Production: Pathophysiology and Potential Strategies for Controlling Necrotic Enteritis. *National Library For Medicine*. 22;10(9):1718.
- Wages, D.P. and Opengart, K. (2003).** Necrotic enteritis. Pages 781–785 in *Disease of Poultry*. Y. M. Saif, ed. 11th ed. Iowa State Press, Ames, IA.
- Wanger, D.D.; Furrow, R.D. and Bradley, B.D. (1983).** Subchronic toxicity of growth promoters in broiler chicks. *Vet. Pathol.*, 20: 253-259.
- Willis, A.T. (1977).** *Anaerobic bacteriology, clinical and laboratory practice*. 3rd ed., 131–133, butter worth, London, Boston.
- Wu, J.; Zhang, W.; Xie, B.; Wu, M.; Tong, X.; Kalpoe, J. and Zhang, D. (2009).** Detection and Toxin Typing of *Clostridium perfringens* in Formalin-Fixed, Paraffin-Embedded Tissue Samples by PCR. *JOURNAL OF CLINICAL MICROBIOLOGY*, p. 807–810.
- Xue, G.; Barekatain, R.; Wu, S.; Choct, M. and Swick, R. (2018).** Dietary L-glutamine supplementation improves growth performance, gut morphology, and serum biochemical indices of broiler chickens during necrotic enteritis challenge. *Poult. Sci.* 0:1–8.
- Xue, Q.S.; Xiao, Y.P. and Lin. J. (2001).** *Theory and technology of culture in vitro*. Scientific Publishing Company, Beijing, China.
- Yuan, J.S.; Reed, A.; Chen, F. and Stewart, C.N. (2006).** Statistical analysis of real-time PCR data. *BMC Bioinformatics*, 7:85.
- Yang, J.; Huang, K.; Wang, J.; Wu, D.; Liu, Z.; Yu, P.; Wei, Z. and Chen, F. (2021).** Combined use of *Bacillus subtilis* yb114, 246 and *Bacillus licheniformis* yb-214, 245 improves body growth performance of Chinese Huainan Partridge shank chickens by enhancing intestinal digestive profiles. *Probiot. Antimicrob.* 13: 327-342.
- Zhang, C.; Zhao, X.; Wang, L.; Yang, L.; Chen, X. and Geng, Z. (2017).** Resveratrol beneficially affects meat quality of heat-stressed broilers which is associated with changes in muscle antioxidant status. *Animal Science Journal*, 88(10): 1569-1574 (doi: 10.1111/asj.12812).
- Zhou, M.; Zeng, D.; Ni, X.; Tu, T.; Yin, Z.; Pan, K. and Jing, B. (2016).** Effects of *Bacillus licheniformis* on the growth performance and expression of lipid metabolism-related genes in broiler chickens challenged with *Clostridium perfringens*-induced necrotic enteritis. *Lipids Health Dis.* 15, 48.
- Zaytsoff, S.J.M.; Lyons, S.M. and Garner, A.M. (2020).** Host responses to *Clostridium perfringens* challenge in a chicken model of chronic stress. *Gut Pathog.* 12, 24.